Abstract:The nuclear factor-κB (NF-κB)-mediated activation of macrophages plays a key role in mucosal immune responses in Crohn’s disease (CD). Moreover, increasing evidence shows that the activation of peroxisome proliferator-activated receptor-γ (PPAR-γ) exerts satisfactory anti-inflammatory effects in experimental colitis models, mostly by suppressing NF-κB-mediated macrophage activation. Therefore, exploring therapeutic strategies to activate PPAR-γ and inhibit the NF-κB pathway in colonic macrophages holds great promise for the treatment of CD. In this study, five novel pyrazole-containing indolizine derivatives (B1, B2, B3, B4 and B5) were successfully synthesized and characterized, and their anti-inflammatory activities for CD treatment were also investigated. Among the five compounds, compound B4 effectively decreased the NF-κB-mediated production of the pro-inflammatory cytokine TNF-α in LPS-stimulated peritoneal macrophages. Moreover, compound B4 significantly ameliorated 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced mouse colitis symptoms, including body weight loss, colonic pathological damage and inflammatory cell infiltration. The results of western blotting and luciferase reporter assays indicated that compound B4 activated PPAR-γ and subsequently suppressed NF-κB activation. Conversely, the addition of the PPAR-γ antagonist GW9662 abrogated the anti-inflammatory effects of compound B4 both in vitro and in vivo. In summary, compound B4 activated the PPAR-γ pathway to inhibit downstream NF-κB signaling, which alleviated experimental colitis. Thus, this compound may serve as a potential therapeutic agent for patients with CD.

A Novel CDK8 Inhibitor with Poly-Substituted Pyridine Core: Discovery and Anti-Inflammatory Activity Evaluation in Vivo

Discovery and Anti-Inflammatory Activity Evaluation of a Novel CDK8 Inhibitor through Upregulation of IL-10 for the Treatment of Inflammatory Bowel Disease In Vivo .

Discovery of a novel cyclin-dependent kinase 8 inhibitor with an oxindole core for anti-inflammatory treatment

Discovery of Novel Imidazo[4,5- c ]quinoline Derivatives to Treat Inflammatory Bowel Disease (IBD) by Inhibiting Multiple Proinflammatory Signaling Pathways and Restoring Intestinal Homeostasis

Discovery of pyrimidine-5-carboxamide derivatives as novel salt-inducible kinases (SIKs) inhibitors for inflammatory bowel disease (IBD) treatment

Design, synthesis, and biological evaluation of indolin-2-one derivatives as novel cyclin-dependent protein kinase 8 (CDK8) inhibitors

Identification of novel indolinone derivatives as CTSC inhibitors to treat inflammatory bowel disease by modulating inflammatory factors

Discovery of 3-(4-(2-((1h-indol-5-yl)amino)-5-fluoropyrimidin-4-yl)-1h-pyrazol-1-yl)propanenitrile Derivatives As Selective TYK2 Inhibitors for the Treatment of Inflammatory Bowel Disease

The discovery of a novel pyrrolo[2,3- b ]pyridine as a selective CDK8 inhibitor offers a new approach against psoriasis

Therapeutic potential of a synthetic dual JAK1/TYK2 inhibitor in inflammatory bowel disease

Structural Modification Based on the Diclofenac Scaffold: Achieving Reduced Colitis Side Effects Through COX-2/NLRP3 Selective Inhibition.

A Novel Pyrazole-Containing Indolizine Derivative Suppresses NF-κB Activation and Protects Against TNBS-induced Colitis Via a PPAR-γ-dependent Pathway

Novel 2-Phenyl-4h-chromen Derivatives: Synthesis and Anti-Inflammatory Activity Evaluation in Vitro and in Vivo

Novel TYK2 Inhibitors with an N-(Methyl-d3)pyridazine-3-carboxamide Skeleton for the Treatment of Autoimmune Diseases

Design and Synthesis of a 2-Amino-pyridine Derivative as a Potent CDK8 Inhibitor for Anti-colorectal Cancer Therapy

Novel TYK2 Inhibitors with an N -(Methyl- d 3 )pyridazine-3-carboxamide Skeleton for the Treatment of Autoimmune Diseases.

Discovery of the Novel 1 H -Pyrrolo[2,3- b ]pyridine Derivative as a Potent Type II CDK8 Inhibitor against Colorectal Cancer

Identification of 3, 4-disubstituted pyridine derivatives as novel CDK8 inhibitors

Discovery of a Series of 4-Amide-thiophene-2-carboxyl Derivatives As Highly Potent P2Y14 Receptor Antagonists for Inflammatory Bowel Disease Treatment

Identification of a Novel Selective CDK9 Inhibitor for the Treatment of CRC: Design, Synthesis, and Biological Activity Evaluation

Design, synthesis and biological evaluation of novel N-(methyl-d3) pyridazine-3-carboxamide derivatives as TYK2 inhibitors